/Idexx%20Laboratories%2C%20Inc_%20outside%20lab-by%20Sundry%20Photography%20via%20iStock.jpg)
With a market cap of $42.3 billion, IDEXX Laboratories, Inc. (IDXX) is a global leader in veterinary diagnostics and software. Founded in 1983, the Westbrook, Maine-based company has grown into a key player in the animal healthcare industry, serving over 50,000 veterinary practices across more than 175 countries.
Companies valued at $10 billion or more are generally described as “large-cap stocks,” and IDEXX Laboratories definitely fits that description. The company's innovative, recurring revenue-driven business model has enabled it to perform in the life sciences space consistently.
IDXX touched its 52-week high of $530.73 recently on Jun. 4 and has climbed 20.5% over the past three months, outpacing the broader Dow Jones Industrial Average’s ($DOWI) 2.3% gain during the same time frame.
In the long term, IDXX is up 27.2% in 2025, outpacing $DOWI's marginal increase. However, IDXX’s 3.5% rise over the past 52 weeks lags behind $DOWI’s 10.3% returns over the same time period.
IDXX has been trading above its 50-day moving average since late April and over its 200-day moving average since early May, indicating an uptrend.
Shares of IDXX jumped 9% after announcing fiscal 2025 Q1 earnings on May 1. Its revenue rose 4% year-over-year to $998 million with a 5% organic growth, driven by continued strength in its Companion Animal Group, Water, and Livestock segments. Its EPS grew 5% to $2.96, supported by gross margin expansion to 62.4% and improved operating margins.
IDEXX also launched its Cancer Dx test for early canine lymphoma detection and raised full-year guidance, projecting revenue of $4.095 to $4.210 billion and EPS of $11.93–$12.43, reflecting confidence in its innovation pipeline and business momentum.
In comparison with its rival, CareDx, Inc. (CDNA) has outperformed IDXX over the past year, gaining 33%. However, CDNA has trailed IDXX’s returns in 2025 with a 7.3% dip.
Among the 11 analysts covering the stock, there is a consensus rating of “Moderate Buy,” and its mean price target of $529.50 implies a marginal upswing potential from the current market prices.
